RU2006125744A - Применение агонистов рецептора сфингозин-1-фосфата (s1p) для лечения дегенеративных заболеваний головного мозга - Google Patents
Применение агонистов рецептора сфингозин-1-фосфата (s1p) для лечения дегенеративных заболеваний головного мозга Download PDFInfo
- Publication number
- RU2006125744A RU2006125744A RU2006125744/15A RU2006125744A RU2006125744A RU 2006125744 A RU2006125744 A RU 2006125744A RU 2006125744/15 A RU2006125744/15 A RU 2006125744/15A RU 2006125744 A RU2006125744 A RU 2006125744A RU 2006125744 A RU2006125744 A RU 2006125744A
- Authority
- RU
- Russia
- Prior art keywords
- group
- alkyl
- pharmaceutically acceptable
- receptor agonist
- acceptable salt
- Prior art date
Links
- 229940044601 receptor agonist Drugs 0.000 title claims abstract 6
- 239000000018 receptor agonist Substances 0.000 title claims abstract 6
- 210000004556 brain Anatomy 0.000 title claims abstract 4
- 229910019142 PO4 Inorganic materials 0.000 title claims 2
- 239000010452 phosphate Substances 0.000 title claims 2
- 230000003412 degenerative effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 206010012289 Dementia Diseases 0.000 claims abstract 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 6
- 230000000750 progressive effect Effects 0.000 claims abstract 6
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 claims abstract 5
- 229940124118 AMPA receptor agonist Drugs 0.000 claims abstract 2
- 239000000774 AMPA receptor agonist Substances 0.000 claims abstract 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract 2
- 239000003795 chemical substances by application Substances 0.000 claims abstract 2
- 239000002664 nootropic agent Substances 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims 8
- 229940121846 Sphingosine 1-phosphate receptor agonist Drugs 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 6
- 208000027866 inflammatory disease Diseases 0.000 claims 6
- -1 carboxyloxy hydroxy Chemical group 0.000 claims 5
- 125000002252 acyl group Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 3
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims 3
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims 3
- 125000003302 alkenyloxy group Chemical group 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 201000004559 cerebral degeneration Diseases 0.000 claims 3
- 230000001149 cognitive effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000003884 phenylalkyl group Chemical group 0.000 claims 3
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000005133 alkynyloxy group Chemical group 0.000 claims 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical group CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000001777 nootropic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000005359 phenoxyalkyl group Chemical group 0.000 claims 1
- 125000002071 phenylalkoxy group Chemical group 0.000 claims 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
1. Применение агониста рецептора сфингозин-1-фосфата (S1P) или его фармацевтически приемлемой соли для приготовления лекарственного средства, предназначенного для лечения прогрессирующей деменции или дегенерации головного мозга.
2. Применение агониста рецептора сфингозин-1-фосфата или его фармацевтически приемлемой соли для приготовления лекарственного средства, предназначенного для лечения связанных с β-амилоидом воспалительных заболеваний или нарушений.
3. Применение агониста рецептора сфингозин-1-фосфата (S1P) или его фармацевтически приемлемой соли для приготовления лекарственного средства, предназначенного для снижения или ингибирования утраты когнитивных способностей.
4. Фармацевтическая композиция, предназначенная для применения при лечении прогрессирующей деменции или дегенерации головного мозга, связанных с β-амилоидом воспалительных заболеваний или нарушений или снижения или ингибирования утраты когнитивных способностей, содержащая агонист рецептора сфингозин-1-фосфата или его фармацевтически приемлемую соль в сочетании с одним или несколькими фармацевтически приемлемыми разбавителями или носителями.
5. Фармацевтическая комбинация, содержащая а) первый агент, представляющий собой агонист S1P-рецептора или его фармацевтически приемлемую соль, и б) коагент, который можно применять для облегчения или лечения дегенеративных заболеваний головного мозга или прогрессирующей деменции.
6. Комбинация по п.5, в которой коагент б), выбран из агониста АМРА-рецептора, ноотропического или противовоспалительного агента или болеутоляющего средства.
7. Способ лечения прогрессирующей деменции или дегенерации головного мозга или связанных с β-амилоидом воспалительных заболеваний или нарушений, или снижения или ингибирования утраты когнитивных способностей у индивидуума, который нуждается в этом, заключающийся в том, что индивидууму вводят терапевтически эффективное количество агониста рецептора сфингозин-1-фосфата (S1P) или его фармацевтически приемлемой соли.
8. Способ по п.7, заключающийся в том, что осуществляют совместное введение, например одновременное или последовательное, с коагентом б), который можно применять для облегчения или лечения дегенеративных заболеваний головного мозга или прогрессирующей деменции.
9. Способ, композиция, комбинация или применение по одному из предыдущих пунктов, в которых агонист S1P-рецептора представляет собой соединение формулы I
в которой R1 обозначает прямую или разветвленную углеродную C12-С22цепь,
где в цепи может находиться связь или гетероатом, выбранные из группы, включающей двойную связь, тройную связь, О, S, NR6, где R6 обозначает Н, алкил, аралкил, ацил или алкоксикарбонил и карбонил, и/или
где может находиться в качестве заместителя алкоксигруппа, алкенилоксигруппа, алкинилоксигруппа, аралкилоксигруппа, ацил, алкиламиногруппа, алкилтиогруппа, ациламиногруппа, алкоксикарбонил, алкоксикарбониламиногруппа, ацилоксигруппа, алкилкарбамоил, нитрогруппа, галоген, аминогруппа, гидроксииминогруппа, гидроксигруппа или карбоксигруппа; или
R1 обозначает
фенилалкил, в котором алкил обозначает прямую или разветвленную углеродную C6-C20цепь; или
фенилалкил, в котором алкил обозначает прямую или разветвленную углеродную C1-C30цепь, где фенилалкил замещен
прямой или разветвленной углеродной C6-C20цепью, необязательно замещенной галогеном,
прямой или разветвленной углеродной C6-C20алкоксигруппой, необязательно замещенной галогеном,
прямой или разветвленной C6-C20алкенилоксигруппой,
фенилалкоксигруппой, галофенилалкоксигруппой, фенилалкоксиалкилом, феноксиалкоксигруппой или феноксиалкилом,
циклоалкилалкилом, замещенным C6-C20алкилом,
гетероарилалкилом, замещенным C6-C20алкилом,
гетероциклическим C6-C20алкилом или
гетероциклическим алкилом, замещенным C2-C20алкилом,
и где алкильный радикал может иметь
в углеродной цепи связь или гетероатом, выбранные из двойной связи, тройной связи, О, S, сульфинила, сульфонила или NR6, где R6 имеет указанные выше значения, и
в качестве заместителя алкоксигруппу, алкенилоксигруппу, алкинилоксигруппу, аралкилоксигруппу, ацил, алкиламиногруппу, алкилтиогруппу, ациламиногруппу, алкоксикарбонил, алкоксикарбониламиногруппу, ацилоксигруппу, алкилкарбамоил, нитрогруппу, галоген, аминогруппу, гидроксигруппу или карбоксигруппу, и R2, R3, R4 и R5, каждый независимо друг от друга, обозначает Н, C1-C4алкил или ацил,
или его фармацевтически приемлемую соль.
10. Способ, композиция, комбинация или применение по п.9, в которых агонист S1P-рецептора представляет собой 2-амино-2-[2-(4-октилфенил)этил]пропан-1,3-диол в свободной форме или в форме фармацевтически приемлемой соли.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0329498.0A GB0329498D0 (en) | 2003-12-19 | 2003-12-19 | Organic compounds |
| GB0329498.0 | 2003-12-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006125744A true RU2006125744A (ru) | 2008-01-27 |
| RU2379030C2 RU2379030C2 (ru) | 2010-01-20 |
Family
ID=30776138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006125744/15A RU2379030C2 (ru) | 2003-12-19 | 2004-12-17 | Применение агонистов рецептора сфингозин-1-фосфата (s1p) для лечения дегенеративных заболеваний головного мозга |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20080139662A1 (ru) |
| EP (2) | EP2213285B1 (ru) |
| JP (2) | JP2007514698A (ru) |
| KR (2) | KR101342244B1 (ru) |
| CN (2) | CN1893934B (ru) |
| AT (1) | ATE474569T1 (ru) |
| AU (1) | AU2004298760B2 (ru) |
| BR (1) | BRPI0417203A (ru) |
| CA (2) | CA2545503C (ru) |
| DE (1) | DE602004028286D1 (ru) |
| ES (2) | ES2348569T3 (ru) |
| GB (1) | GB0329498D0 (ru) |
| HK (1) | HK1097458A1 (ru) |
| MX (1) | MXPA06006924A (ru) |
| PL (1) | PL1713459T3 (ru) |
| PT (1) | PT1713459E (ru) |
| RU (1) | RU2379030C2 (ru) |
| WO (1) | WO2005058295A2 (ru) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009002993A (es) * | 2006-09-26 | 2009-04-01 | Novartis Ag | Composiciones farmaceuticas que comprenden un modulador de s1p. |
| EP1905434A1 (en) * | 2006-09-26 | 2008-04-02 | Novartis AG | Organic compounds comprising an S1P receptor agonist and their therapeutic use |
| KR20180023049A (ko) | 2008-07-23 | 2018-03-06 | 아레나 파마슈티칼스, 인크. | 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체 |
| PT2342205T (pt) | 2008-08-27 | 2016-07-28 | Arena Pharm Inc | Derivados de ácido tricíclico substituído como agonistas de recetor s1p1 úteis no tratamento de distúrbios autoimunes e inflamatórios |
| EP2177521A1 (en) | 2008-10-14 | 2010-04-21 | Almirall, S.A. | New 2-Amidothiadiazole Derivatives |
| EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| US20120128666A1 (en) * | 2009-06-24 | 2012-05-24 | Lpath, Inc. | Methods of increasing neuronal differentiation using antibodies to lysophosphatidic acid |
| UY32858A (es) | 2009-08-31 | 2011-03-31 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina como moduladores de sip |
| EP2305660A1 (en) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
| EP2343287A1 (en) | 2009-12-10 | 2011-07-13 | Almirall, S.A. | New 2-aminothiadiazole derivatives |
| WO2011094008A1 (en) | 2010-01-27 | 2011-08-04 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| RU2702198C2 (ru) | 2010-03-01 | 2019-10-04 | Янссен Байотек, Инк. | Способы очистки клеток, производных от плюрипотентных стволовых клеток |
| ES2558087T3 (es) | 2010-03-03 | 2016-02-01 | Arena Pharmaceuticals, Inc. | Procesos para la preparación de moduladores del receptor S1P1 y formas cristalinas de los mismos |
| EP2366702A1 (en) | 2010-03-18 | 2011-09-21 | Almirall, S.A. | New oxadiazole derivatives |
| EP2390252A1 (en) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| TWI543984B (zh) | 2010-07-09 | 2016-08-01 | 艾伯維公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| TW201206893A (en) | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
| TWI522361B (zh) | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
| KR102203056B1 (ko) | 2011-12-22 | 2021-01-14 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화 |
| RU2482842C1 (ru) * | 2012-04-26 | 2013-05-27 | Открытое акционерное общество "Новосибхимфарм" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| EP2938724B1 (en) | 2012-12-31 | 2020-10-28 | Janssen Biotech, Inc. | Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells |
| BR112015015714A2 (pt) | 2012-12-31 | 2017-07-11 | Janssen Biotech Inc | suspensão e aglomeração de células pluripotentes humanas para diferenciação em célu-las endócrinas pancreáticas |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| EP2878339A1 (en) * | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
| EP4445956A2 (en) | 2015-01-06 | 2024-10-16 | Arena Pharmaceuticals, Inc. | Compound for use in treating conditions related to the s1p1 receptor |
| WO2016209809A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders |
| WO2018151873A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| MA47503A (fr) | 2017-02-16 | 2021-04-21 | Arena Pharm Inc | Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales |
| KR20210074291A (ko) | 2018-09-06 | 2021-06-21 | 아레나 파마슈티칼스, 인크. | 자가면역 및 염증성 장애의 치료에 유용한 화합물 |
| US20220296620A1 (en) * | 2019-08-07 | 2022-09-22 | National University Corporation Tokyo Medical And Dental University | Agent for preventing or treating mild cognitive impairment |
| US11535632B2 (en) | 2019-10-31 | 2022-12-27 | ESCAPE Bio, Inc. | Solid forms of an S1P-receptor modulator |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3154742B2 (ja) * | 1991-04-30 | 2001-04-09 | 日本石油化学株式会社 | 哺乳類の動脈硬化症治療剤 |
| DK0627406T3 (da) | 1992-10-21 | 1999-07-12 | Taito Co | 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler |
| ES2171191T3 (es) | 1994-08-22 | 2002-09-01 | Mitsubishi Pharma Corp | Compuesto de benceno y uso medicinal del mismo. |
| DE69618765T2 (de) * | 1995-02-15 | 2002-10-17 | Takeda Chemical Industries, Ltd. | Verwendung von kompocedinderivaten zur inhibierung der bildung oder sekretion von beta-amyloid-protein |
| DE19513630A1 (de) * | 1995-04-05 | 1996-10-10 | Schering Ag | Neue Verwendung von AMPA-Agonisten |
| EP0812588B1 (en) * | 1995-12-28 | 2004-10-13 | Mitsubishi Pharma Corporation | Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder |
| WO1997048391A2 (en) * | 1996-06-21 | 1997-12-24 | Advanced Research And Technology Institute | Methods and compositions comprising r-ibuprofen |
| ITMI962356A1 (it) * | 1996-11-13 | 1998-05-13 | Uni Degli Studi Di Brescia D I | Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di |
| DK0990440T3 (da) * | 1997-02-27 | 2009-02-23 | Novartis Ag | Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid |
| PT1002792E (pt) | 1997-04-04 | 2004-12-31 | Mitsubishi Pharma Corp | Compostos de 2-aminopropano-1,3-diol, sua utilizacao medicinal e intermediariosda sintese dos mesmos |
| JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| CA2330329C (en) * | 1999-02-26 | 2009-08-25 | Marcus Keep | Cerebrospinal and vascular pharmaceutical composition and process for preparing the same |
| US6420369B1 (en) * | 1999-05-24 | 2002-07-16 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating dementia |
| CA2310990A1 (en) * | 2000-04-03 | 2000-10-09 | Michael Pontecorvo | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
| AU6950301A (en) | 2000-07-13 | 2002-01-30 | Sankyo Co | Amino alcohol derivatives |
| CA2421893A1 (en) * | 2000-08-31 | 2002-03-07 | Merck And Co., Inc. | Phosphate derivatives as immunoregulatory agents |
| US20030013692A1 (en) * | 2001-01-19 | 2003-01-16 | Gullans Steven R. | Methods of treating neurological disorders |
| US7326801B2 (en) * | 2001-03-26 | 2008-02-05 | Novartis Ag | 2-amino-propanol derivatives |
| JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
| WO2003011270A1 (de) * | 2001-07-31 | 2003-02-13 | Lothar Saiger | Mittel zur behandlung von depressionen enthaltend ein lokalanästhetikum |
| US6960692B2 (en) | 2001-09-27 | 2005-11-01 | Kyorin Pharmaceutical Co., Ltd. | Diaryl sulfide derivative, addition salt thereof, and immunosuppressant |
| US6963012B2 (en) * | 2001-09-27 | 2005-11-08 | Kyorin Pharmaceutical Co., Ltd. | Diaryl ether derivative, addition salt thereof, and immunosuppressant |
| GB0129260D0 (en) * | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| TWI252111B (en) * | 2001-12-14 | 2006-04-01 | Solvay Pharm Gmbh | Matrix film tablet with controlled release of a natural mixture of conjugated estrogens |
| EP1470137B1 (en) * | 2002-01-18 | 2009-09-02 | Merck & Co., Inc. | Edg receptor agonists |
| US20050070506A1 (en) | 2002-01-18 | 2005-03-31 | Doherty George A. | Selective s1p1/edg1 receptor agonists |
| US20040014662A1 (en) * | 2002-05-08 | 2004-01-22 | Per Lindquist | Modulation of neural stem cells and neural progenitor cells |
| GB0217152D0 (en) * | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
| CA2497067A1 (en) * | 2002-09-13 | 2004-03-25 | Novartis Ag | Amino-propanol derivatives |
| US6776328B2 (en) | 2002-09-17 | 2004-08-17 | The Boeing Company | Radiation assisted friction welding |
| CN1708293A (zh) * | 2002-09-24 | 2005-12-14 | 诺瓦提斯公司 | 治疗脱髓鞘疾病的鞘氨醇－1－磷酸受体激动剂 |
| JP4603531B2 (ja) * | 2003-04-30 | 2010-12-22 | ノバルティス アーゲー | スフィンゴシン−１−ホスフェートレセプターモジュレーターとしての、アミノプロパノール誘導体 |
| BRPI0411831A (pt) * | 2003-06-24 | 2006-08-08 | Univ Connecticut | métodos de inibição da permeabilidade vascular e apoptose |
| US20050090520A1 (en) * | 2003-09-12 | 2005-04-28 | Per Lindquist | Treatment of disease or injury of the nervous system with FTY720 |
| US7638637B2 (en) * | 2003-11-03 | 2009-12-29 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
-
2003
- 2003-12-19 GB GBGB0329498.0A patent/GB0329498D0/en not_active Ceased
-
2004
- 2004-12-17 ES ES04804037T patent/ES2348569T3/es active Active
- 2004-12-17 BR BRPI0417203-5A patent/BRPI0417203A/pt not_active IP Right Cessation
- 2004-12-17 KR KR1020127019200A patent/KR101342244B1/ko not_active IP Right Cessation
- 2004-12-17 EP EP09177200.4A patent/EP2213285B1/en not_active Not-in-force
- 2004-12-17 JP JP2006544366A patent/JP2007514698A/ja active Pending
- 2004-12-17 US US10/583,106 patent/US20080139662A1/en not_active Abandoned
- 2004-12-17 CA CA2545503A patent/CA2545503C/en not_active Expired - Fee Related
- 2004-12-17 AT AT04804037T patent/ATE474569T1/de active
- 2004-12-17 CN CN2004800378611A patent/CN1893934B/zh not_active Expired - Fee Related
- 2004-12-17 AU AU2004298760A patent/AU2004298760B2/en not_active Ceased
- 2004-12-17 PL PL04804037T patent/PL1713459T3/pl unknown
- 2004-12-17 RU RU2006125744/15A patent/RU2379030C2/ru not_active IP Right Cessation
- 2004-12-17 ES ES09177200.4T patent/ES2444717T3/es active Active
- 2004-12-17 KR KR1020067011896A patent/KR101232934B1/ko not_active IP Right Cessation
- 2004-12-17 MX MXPA06006924A patent/MXPA06006924A/es active IP Right Grant
- 2004-12-17 WO PCT/EP2004/014436 patent/WO2005058295A2/en active Application Filing
- 2004-12-17 DE DE602004028286T patent/DE602004028286D1/de active Active
- 2004-12-17 EP EP04804037A patent/EP1713459B1/en not_active Not-in-force
- 2004-12-17 CA CA2792467A patent/CA2792467A1/en not_active Abandoned
- 2004-12-17 PT PT04804037T patent/PT1713459E/pt unknown
- 2004-12-17 CN CN2010101454323A patent/CN101791406B/zh not_active Expired - Fee Related
-
2007
- 2007-03-29 HK HK07103403.8A patent/HK1097458A1/xx not_active IP Right Cessation
-
2010
- 2010-09-17 US US12/884,953 patent/US8519006B2/en not_active Expired - Fee Related
-
2011
- 2011-04-28 JP JP2011100640A patent/JP5469122B2/ja not_active Expired - Fee Related
-
2013
- 2013-06-18 US US13/920,329 patent/US20130281541A1/en not_active Abandoned
- 2013-12-02 US US14/093,975 patent/US20140162964A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006125744A (ru) | Применение агонистов рецептора сфингозин-1-фосфата (s1p) для лечения дегенеративных заболеваний головного мозга | |
| RU2011115499A (ru) | Применение модуляторов рецептора s1p в офтальмологии | |
| JP2005536475A5 (ru) | ||
| US9265754B2 (en) | Use of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid in treating symptoms associated with rett syndrome | |
| JP2010100637A5 (ru) | ||
| JP2005506308A5 (ru) | ||
| RU2009102278A (ru) | Модуляторы рецептора s1p для лечения рассеянного склероза | |
| BR0314760A (pt) | Compostos orgânicos | |
| JP2010526820A (ja) | 気分障害、睡眠障害、または注意欠陥障害を治療するドロキシドパおよびその医薬組成物 | |
| EA023500B1 (ru) | Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты | |
| RU2008146816A (ru) | Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол | |
| RU2010100945A (ru) | Способы и композиции для стимулирования нейрогенеза и ингибирования дегенерации нейронов с использованием изотиазолопиримидинонов | |
| JP2010537999A (ja) | 麻酔薬節約効果を得るためのｎｍｄａ拮抗薬を用いる組成物および方法 | |
| FR2829027A1 (fr) | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson | |
| US10077236B2 (en) | Azacyclic constrained analogs of FTY720 | |
| JP4276837B2 (ja) | 双極性障害の予防もしくは治療における使用のためのカルバメート化合物 | |
| RU2336077C2 (ru) | Альфа-аминоамидные производные, применимые в качестве антимигренозных средств | |
| JP2005532321A (ja) | 呼吸器の疾患および状態の、選択的ｉＮＯＳ阻害剤とＰＤＥ阻害剤による治療方法、ならびにそのための組成物 | |
| JP5198293B2 (ja) | アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤 | |
| JP5271473B2 (ja) | 神経障害性疼痛ならびに群発性頭痛および偏頭痛に関連する疼痛の予防もしくは治療における使用のためのカルバメート化合物 | |
| JP2020533402A5 (ru) | ||
| MX2021008213A (es) | Derivados de (2,5-dioxopirrolidina-1-il)(fenil)-acetamida y su uso en el tratamiento de enfermedades neurologicas. | |
| AU2007337097A1 (en) | Alpha-2B adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain | |
| US20170119702A1 (en) | Dosage Regimen of Diaryl Sulfide Derivatives | |
| RU2003104804A (ru) | Ингибиторы матриксной металлопротеиназы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20161218 |